GITNUXREPORT 2026

Biopharmaceutical Industry Statistics

The global biopharmaceutical industry is large, growing, and driven by oncology and immunology innovations.

Alexander Schmidt

Research Analyst specializing in technology and digital transformation trends.

First published: Feb 13, 2026

Our Commitment to Accuracy

Rigorous fact-checking · Reputable sources · Regular updatesLearn more

Statistic 1

Biopharma industry employs 5.1 million people worldwide in 2023.

Statistic 2

U.S. biopharma sector supports 4.7 million jobs directly and indirectly in 2022.

Statistic 3

Biopharma manufacturing workforce in Europe: 800,000 in 2023.

Statistic 4

India biopharma employs 3.5 million, largest exporter workforce.

Statistic 5

Women represent 48% of biopharma workforce globally in 2023.

Statistic 6

STEM PhDs in biopharma jobs grew 15% YoY to 120,000 in U.S. 2023.

Statistic 7

Biopharma R&D roles account for 35% of total employment, 1.8 million jobs.

Statistic 8

Contract manufacturing organizations (CMOs) employ 500,000 in biopharma supply chain 2023.

Statistic 9

Switzerland biopharma workforce: 45,000 highly skilled jobs in 2022.

Statistic 10

Biopharma digital roles (data scientists) increased 25% to 50,000 globally 2023.

Statistic 11

U.K. biopharma employs 250,000, contributing £108 billion to economy.

Statistic 12

China biopharma workforce reached 2.5 million in 2023, up 10%.

Statistic 13

Biopharma sales force size globally: 300,000 reps in 2022.

Statistic 14

Regulatory affairs professionals in biopharma: 100,000 worldwide 2023.

Statistic 15

Biopharma quality control jobs: 400,000, 20% growth since 2018.

Statistic 16

Average biopharma salary in U.S.: $130,000 in 2023.

Statistic 17

Ireland biopharma employs 50,000, 25% of manufacturing output.

Statistic 18

Biopharma apprenticeships trained 20,000 new workers in EU 2022.

Statistic 19

Global biopharma clinical trial staff: 1.2 million in 2023.

Statistic 20

The global biopharmaceutical market size reached $486.4 billion in 2022 and is projected to grow to $712.4 billion by 2028 at a CAGR of 6.6%.

Statistic 21

Biopharma revenue grew 9% to $1.48 trillion in 2022, driven by oncology and immunology segments.

Statistic 22

North America holds 42% share of the global biopharma market valued at $204.5 billion in 2023.

Statistic 23

The biologics market within biopharma is expected to reach $637 billion by 2030, growing at 10.3% CAGR from 2023.

Statistic 24

Asia-Pacific biopharma market expanded at 8.2% CAGR from 2018-2023, reaching $120 billion in 2023.

Statistic 25

U.S. biopharma market was valued at $350 billion in 2022, accounting for 38% of global spending.

Statistic 26

Biosimilars market in biopharma hit $25.1 billion globally in 2022, projected to $132 billion by 2030.

Statistic 27

Europe biopharma sector generated €250 billion in sales in 2022, with 7% YoY growth.

Statistic 28

Cell and gene therapy market, a biopharma subset, valued at $11.5 billion in 2023, to reach $45.8 billion by 2028.

Statistic 29

Latin America biopharma market grew to $45 billion in 2023 at 5.4% CAGR since 2019.

Statistic 30

Middle East & Africa biopharma market size was $18.2 billion in 2022, expected to grow at 7.1% CAGR to 2030.

Statistic 31

mRNA therapeutics market in biopharma surged to $42 billion in 2023 post-COVID vaccines.

Statistic 32

Global biopharma outsourcing market valued at $58.4 billion in 2023, projected $115.2 billion by 2030.

Statistic 33

Oncology biopharma segment market size was $208 billion in 2022, fastest growing at 11.2% CAGR.

Statistic 34

Immunology biopharma market reached $152 billion in 2023, with 12% annual growth.

Statistic 35

Rare diseases biopharma market valued at $186 billion in 2022, to hit $350 billion by 2030.

Statistic 36

ADC (antibody-drug conjugates) biopharma market was $8.4 billion in 2023, projected $25 billion by 2028.

Statistic 37

Global biopharma CDMO market size stood at $22.5 billion in 2023, growing at 12.8% CAGR.

Statistic 38

Personalized medicine biopharma segment reached $529 billion in 2023, CAGR 8.2% to 2030.

Statistic 39

Vaccine biopharma market valued at $61.5 billion in 2023, expected $107.5 billion by 2030.

Statistic 40

Biopharma companies invested $96 billion in R&D in 2022, up 5% from prior year.

Statistic 41

Top 20 biopharma firms spent average $6.2 billion per company on R&D in 2022.

Statistic 42

Phase III clinical trials in biopharma cost average $255 million per drug in 2023 estimates.

Statistic 43

Biopharma pipeline includes 21,000+ molecules in development as of 2023.

Statistic 44

Oncology R&D investment by biopharma reached $52 billion in 2022, 28% of total R&D.

Statistic 45

Immunology R&D spend was $28 billion in 2022, second largest category.

Statistic 46

Biopharma AI in drug discovery investment hit $2.5 billion in 2023.

Statistic 47

Average biopharma R&D intensity (R&D/sales) was 20.5% for top firms in 2022.

Statistic 48

Gene therapy R&D pipeline has 2,500+ candidates in 2023.

Statistic 49

CAR-T cell therapies in pipeline: 1,050 as of mid-2023.

Statistic 50

Biopharma CRISPR/Cas9 trials numbered 45 in 2023.

Statistic 51

Global biopharma R&D spending forecast to reach $150 billion by 2026.

Statistic 52

Small biopharma firms (<$500M revenue) R&D spend averaged 25% of sales in 2022.

Statistic 53

Neuroscience R&D investment dropped to $5.8 billion in 2022, down 2%.

Statistic 54

Biopharma partnerships for R&D totaled 1,200 deals worth $180 billion in 2023.

Statistic 55

Average cost to develop a biopharma biologic is $2.6 billion from discovery to approval.

Statistic 56

Biopharma M&A deals for R&D assets: 450 in 2023, value $120 billion.

Statistic 57

U.S. biopharma R&D tax credits claimed $15 billion in 2022.

Statistic 58

FDA approved 55 novel biopharma drugs in 2022.

Statistic 59

EMA approved 38 new biopharma products in 2023.

Statistic 60

Biosimilar approvals by FDA: 40 since 2015 through 2023.

Statistic 61

China NMPA approved 25 cell/gene therapies by end-2023.

Statistic 62

U.S. breakthrough therapy designations for biopharma: 120 in 2022.

Statistic 63

Orphan drug designations by FDA: 600 for biopharma in 2023.

Statistic 64

PMDA Japan approved 15 novel biologics in 2023.

Statistic 65

Global Phase III biopharma trials active: 2,500 in 2023.

Statistic 66

FDA warning letters to biopharma firms: 45 in 2023.

Statistic 67

EU GMP inspections for biopharma: 1,200 conducted in 2022.

Statistic 68

ANDA approvals for biopharma generics: 250 by US FDA 2023.

Statistic 69

Health Canada approved 20 biopharma NDS in 2023.

Statistic 70

Biopharma patents filed globally: 45,000 in 2022.

Statistic 71

Fast track designations FDA biopharma: 150 in 2023.

Statistic 72

BLA submissions to FDA: 85 in 2023.

Statistic 73

Post-approval changes for biopharma: 5,000 reviewed by EMA 2022.

Statistic 74

Australia TGA approved 12 novel biopharma drugs 2023.

Statistic 75

Biopharma recall actions by FDA: 120 in 2023.

Statistic 76

Global harmonization ICH guidelines adopted by 50 regulators for biopharma.

Statistic 77

Top 10 biopharma firms generated $550 billion in revenue in 2022.

Statistic 78

Pfizer biopharma sales: $100.3 billion in 2022, led by Comirnaty.

Statistic 79

Roche pharma sales: $65.4 billion in 2022, 70% biologics.

Statistic 80

Johnson & Johnson biopharma revenue: $54.1 billion in 2023.

Statistic 81

Novartis sales from biologics: $28.5 billion in 2022.

Statistic 82

Merck & Co. Keytruda sales: $25 billion in 2023.

Statistic 83

AbbVie Humira sales peaked at $20.7 billion in 2022 before biosimilars.

Statistic 84

AstraZeneca oncology sales: $18.2 billion in 2023.

Statistic 85

Sanofi biopharma revenue: $46.7 billion in 2022.

Statistic 86

Gilead Sciences sales: $27.1 billion in 2022, led by antivirals.

Statistic 87

Bristol Myers Squibb Opdivo sales: $9.0 billion in 2023.

Statistic 88

Regeneron Eylea sales: $9.4 billion in 2022.

Statistic 89

Biogen sales: $9.8 billion in 2022.

Statistic 90

Vertex Pharmaceuticals revenue: $9.9 billion in 2023, cystic fibrosis focus.

Statistic 91

Amgen Prolia sales: $4.2 billion in 2023.

Statistic 92

Eli Lilly Mounjaro sales: $5.2 billion in 2023 (biopharma adjacent).

Statistic 93

Biopharma top 50 firms total revenue: $1.2 trillion in 2022.

Statistic 94

Biosimilar sales globally: $28 billion in 2023.

Statistic 95

CAR-T therapies global sales: $3.5 billion in 2023.

1/95

Sources

Trusted by 500+ publications

+497

From a market poised to hit $712 billion by 2028 to a pipeline teeming with over 21,000 molecules, the biopharmaceutical industry is not just growing—it's fundamentally reshaping the future of medicine.

Key Takeaways

The global biopharmaceutical market size reached $486.4 billion in 2022 and is projected to grow to $712.4 billion by 2028 at a CAGR of 6.6%.
Biopharma revenue grew 9% to $1.48 trillion in 2022, driven by oncology and immunology segments.
North America holds 42% share of the global biopharma market valued at $204.5 billion in 2023.
Biopharma companies invested $96 billion in R&D in 2022, up 5% from prior year.
Top 20 biopharma firms spent average $6.2 billion per company on R&D in 2022.
Phase III clinical trials in biopharma cost average $255 million per drug in 2023 estimates.
Biopharma industry employs 5.1 million people worldwide in 2023.
U.S. biopharma sector supports 4.7 million jobs directly and indirectly in 2022.
Biopharma manufacturing workforce in Europe: 800,000 in 2023.
FDA approved 55 novel biopharma drugs in 2022.
EMA approved 38 new biopharma products in 2023.
Biosimilar approvals by FDA: 40 since 2015 through 2023.
Top 10 biopharma firms generated $550 billion in revenue in 2022.
Pfizer biopharma sales: $100.3 billion in 2022, led by Comirnaty.
Roche pharma sales: $65.4 billion in 2022, 70% biologics.

The global biopharmaceutical industry is large, growing, and driven by oncology and immunology innovations.

Employment and Workforce

Biopharma industry employs 5.1 million people worldwide in 2023.
U.S. biopharma sector supports 4.7 million jobs directly and indirectly in 2022.
Biopharma manufacturing workforce in Europe: 800,000 in 2023.
India biopharma employs 3.5 million, largest exporter workforce.
Women represent 48% of biopharma workforce globally in 2023.
STEM PhDs in biopharma jobs grew 15% YoY to 120,000 in U.S. 2023.
Biopharma R&D roles account for 35% of total employment, 1.8 million jobs.
Contract manufacturing organizations (CMOs) employ 500,000 in biopharma supply chain 2023.
Switzerland biopharma workforce: 45,000 highly skilled jobs in 2022.
Biopharma digital roles (data scientists) increased 25% to 50,000 globally 2023.
U.K. biopharma employs 250,000, contributing £108 billion to economy.
China biopharma workforce reached 2.5 million in 2023, up 10%.
Biopharma sales force size globally: 300,000 reps in 2022.
Regulatory affairs professionals in biopharma: 100,000 worldwide 2023.
Biopharma quality control jobs: 400,000, 20% growth since 2018.
Average biopharma salary in U.S.: $130,000 in 2023.
Ireland biopharma employs 50,000, 25% of manufacturing output.
Biopharma apprenticeships trained 20,000 new workers in EU 2022.
Global biopharma clinical trial staff: 1.2 million in 2023.

Employment and Workforce Interpretation

Behind every one of our 5.1 million global colleagues lies not just a job, but a relentless, highly skilled, and increasingly diverse army of researchers, manufacturers, regulators, and digital pioneers—all united by the daunting yet vital mission of turning molecules into medicines while somehow also remembering to file all the paperwork.

Market Size and Growth

The global biopharmaceutical market size reached $486.4 billion in 2022 and is projected to grow to $712.4 billion by 2028 at a CAGR of 6.6%.
Biopharma revenue grew 9% to $1.48 trillion in 2022, driven by oncology and immunology segments.
North America holds 42% share of the global biopharma market valued at $204.5 billion in 2023.
The biologics market within biopharma is expected to reach $637 billion by 2030, growing at 10.3% CAGR from 2023.
Asia-Pacific biopharma market expanded at 8.2% CAGR from 2018-2023, reaching $120 billion in 2023.
U.S. biopharma market was valued at $350 billion in 2022, accounting for 38% of global spending.
Biosimilars market in biopharma hit $25.1 billion globally in 2022, projected to $132 billion by 2030.
Europe biopharma sector generated €250 billion in sales in 2022, with 7% YoY growth.
Cell and gene therapy market, a biopharma subset, valued at $11.5 billion in 2023, to reach $45.8 billion by 2028.
Latin America biopharma market grew to $45 billion in 2023 at 5.4% CAGR since 2019.
Middle East & Africa biopharma market size was $18.2 billion in 2022, expected to grow at 7.1% CAGR to 2030.
mRNA therapeutics market in biopharma surged to $42 billion in 2023 post-COVID vaccines.
Global biopharma outsourcing market valued at $58.4 billion in 2023, projected $115.2 billion by 2030.
Oncology biopharma segment market size was $208 billion in 2022, fastest growing at 11.2% CAGR.
Immunology biopharma market reached $152 billion in 2023, with 12% annual growth.
Rare diseases biopharma market valued at $186 billion in 2022, to hit $350 billion by 2030.
ADC (antibody-drug conjugates) biopharma market was $8.4 billion in 2023, projected $25 billion by 2028.
Global biopharma CDMO market size stood at $22.5 billion in 2023, growing at 12.8% CAGR.
Personalized medicine biopharma segment reached $529 billion in 2023, CAGR 8.2% to 2030.
Vaccine biopharma market valued at $61.5 billion in 2023, expected $107.5 billion by 2030.

Market Size and Growth Interpretation

Despite North America's dominance with over 40% of the market, the global biopharmaceutical industry's staggering half-trillion-dollar annual revenue is less a testament to a single region and more a relentless, oncology-driven expansion, where even specialized fields like cell therapy and mRNA are becoming multi-billion-dollar ventures practically overnight.

R&D Expenditure

Biopharma companies invested $96 billion in R&D in 2022, up 5% from prior year.
Top 20 biopharma firms spent average $6.2 billion per company on R&D in 2022.
Phase III clinical trials in biopharma cost average $255 million per drug in 2023 estimates.
Biopharma pipeline includes 21,000+ molecules in development as of 2023.
Oncology R&D investment by biopharma reached $52 billion in 2022, 28% of total R&D.
Immunology R&D spend was $28 billion in 2022, second largest category.
Biopharma AI in drug discovery investment hit $2.5 billion in 2023.
Average biopharma R&D intensity (R&D/sales) was 20.5% for top firms in 2022.
Gene therapy R&D pipeline has 2,500+ candidates in 2023.
CAR-T cell therapies in pipeline: 1,050 as of mid-2023.
Biopharma CRISPR/Cas9 trials numbered 45 in 2023.
Global biopharma R&D spending forecast to reach $150 billion by 2026.
Small biopharma firms (<$500M revenue) R&D spend averaged 25% of sales in 2022.
Neuroscience R&D investment dropped to $5.8 billion in 2022, down 2%.
Biopharma partnerships for R&D totaled 1,200 deals worth $180 billion in 2023.
Average cost to develop a biopharma biologic is $2.6 billion from discovery to approval.
Biopharma M&A deals for R&D assets: 450 in 2023, value $120 billion.
U.S. biopharma R&D tax credits claimed $15 billion in 2022.

R&D Expenditure Interpretation

It’s a high-stakes, billion-dollar casino where the house bets massively on thousands of long shots, hoping a few will pay off in lifesaving jackpots.

Regulatory and Approvals

FDA approved 55 novel biopharma drugs in 2022.
EMA approved 38 new biopharma products in 2023.
Biosimilar approvals by FDA: 40 since 2015 through 2023.
China NMPA approved 25 cell/gene therapies by end-2023.
U.S. breakthrough therapy designations for biopharma: 120 in 2022.
Orphan drug designations by FDA: 600 for biopharma in 2023.
PMDA Japan approved 15 novel biologics in 2023.
Global Phase III biopharma trials active: 2,500 in 2023.
FDA warning letters to biopharma firms: 45 in 2023.
EU GMP inspections for biopharma: 1,200 conducted in 2022.
ANDA approvals for biopharma generics: 250 by US FDA 2023.
Health Canada approved 20 biopharma NDS in 2023.
Biopharma patents filed globally: 45,000 in 2022.
Fast track designations FDA biopharma: 150 in 2023.
BLA submissions to FDA: 85 in 2023.
Post-approval changes for biopharma: 5,000 reviewed by EMA 2022.
Australia TGA approved 12 novel biopharma drugs 2023.
Biopharma recall actions by FDA: 120 in 2023.
Global harmonization ICH guidelines adopted by 50 regulators for biopharma.

Regulatory and Approvals Interpretation

The regulatory landscape is a frenetic but vital dance, with one hand furiously approving groundbreaking and orphaned therapies at a record pace while the other hand is just as busy inspecting, warning, and recalling, all under a growing global framework trying to keep up with the sheer volume of innovation and oversight required.

Sales and Revenue

Top 10 biopharma firms generated $550 billion in revenue in 2022.
Pfizer biopharma sales: $100.3 billion in 2022, led by Comirnaty.
Roche pharma sales: $65.4 billion in 2022, 70% biologics.
Johnson & Johnson biopharma revenue: $54.1 billion in 2023.
Novartis sales from biologics: $28.5 billion in 2022.
Merck & Co. Keytruda sales: $25 billion in 2023.
AbbVie Humira sales peaked at $20.7 billion in 2022 before biosimilars.
AstraZeneca oncology sales: $18.2 billion in 2023.
Sanofi biopharma revenue: $46.7 billion in 2022.
Gilead Sciences sales: $27.1 billion in 2022, led by antivirals.
Bristol Myers Squibb Opdivo sales: $9.0 billion in 2023.
Regeneron Eylea sales: $9.4 billion in 2022.
Biogen sales: $9.8 billion in 2022.
Vertex Pharmaceuticals revenue: $9.9 billion in 2023, cystic fibrosis focus.
Amgen Prolia sales: $4.2 billion in 2023.
Eli Lilly Mounjaro sales: $5.2 billion in 2023 (biopharma adjacent).
Biopharma top 50 firms total revenue: $1.2 trillion in 2022.
Biosimilar sales globally: $28 billion in 2023.
CAR-T therapies global sales: $3.5 billion in 2023.

Sales and Revenue Interpretation

While the industry's trillion-dollar machinery thrives on a handful of blockbuster drugs—each a scientific and commercial moonshot—it's a stark reminder that its immense value is both concentrated in a few golden tickets and increasingly challenged by the biosimilar aftershocks they inevitably create.